{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T20:05:32Z","timestamp":1789761932742,"version":"4.0.1"},"reference-count":29,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2024,3,18]],"date-time":"2024-03-18T00:00:00Z","timestamp":1710720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["R01\u2010HS\u2010028024"],"award-info":[{"award-number":["R01\u2010HS\u2010028024"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acrjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Arthritis Care &amp; Research"],"published-print":{"date-parts":[[2024,7]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>We combined claims and electronic health record (EHR) data to provide contemporary and accurate estimates of latent tuberculosis (TB) screening among new users of a biologic or targeted synthetic disease\u2010modifying antirheumatic drug (b\/tsDMARD) and assess potential gaps in testing by drug type, patient characteristics, and practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Our denominator population was patients in the Rheumatology Informatics System for Effectiveness (RISE) registry and Medicare using a b\/tsDMARD in 2018 without a claim or prescription in the year prior. TB screening was assessed in both Medicare and RISE 1 and 3 years before the medication start date. We calculated the proportion screened overall, by medication class, and by practice. We tested for demographic differences in screening using logistic regression.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the year before drug starts, 65.6% of patients had any TB screening; in a 3\u2010year window, 72.9% had any TB screening. Rates of screening within 1 year by drug type were greater or equal to the overall screening rate for most drugs except for JAK inhibitors (JAKis) (46%) and interleukin\u201017 inhibitors (IL\u201017is) (11.5%). A lower proportion of Hispanic and Asian patients were screened compared with White patients. Practice screening rates ranged from 20.0% to 92.9% of patients within 1 year.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We report higher screening rates than have previously been published because of combining claims and EHR data. However, important safety gaps remain, namely, reduced screening among new users of a JAKi or IL\u201017i and among Asian and Hispanic patients, as well as low\u2010performing practices. Educational initiatives, team\u2010based care delivery, task shifting, and technological interventions to address observed gaps in patient safety procedures are needed.<\/jats:p><\/jats:sec>","DOI":"10.1002\/acr.25318","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T18:47:20Z","timestamp":1709059640000},"page":"1037-1044","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Latent Tuberculosis Screening Among New Users of a Biologic or Targeted Synthetic <scp>Disease\u2010Modifying<\/scp> Antirheumatic Drug: Gaps in Screening Overall and Among Janus Kinase Inhibitors"],"prefix":"10.1002","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8435-8994","authenticated-orcid":false,"given":"Eric T.","family":"Roberts","sequence":"first","affiliation":[{"name":"University of California  San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2687-5043","authenticated-orcid":false,"given":"Gabriela","family":"Schmajuk","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, and San Francisco Veterans Affairs Medical Center  San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3298-2112","authenticated-orcid":false,"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"University of California  San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Murrill","sequence":"additional","affiliation":[{"name":"University of California  San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3508-4094","authenticated-orcid":false,"given":"Jinoos","family":"Yazdany","sequence":"additional","affiliation":[{"name":"University of California, San Francisco, and Zuckerberg San Francisco General Hospital  San Francisco California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,3,18]]},"reference":[{"issue":"30","key":"e_1_2_6_2_1","first-page":"683","article-title":"Tuberculosis associated with blocking agents against tumor necrosis factor\u2010alpha\u2014California, 2002\u20102003","volume":"53","author":"Centers for Disease Control and Prevention","year":"2004","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11137"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011110"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223335"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21641"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X20930116"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0b013e3182937094"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcjq.2018.12.003"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2014.07.006"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24444"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2020.03.003"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.359"},{"key":"e_1_2_6_14_1","unstructured":"WilsonJ BockA.The benefit of using both claims data and electronic medical record data in health care analysis. Optum Insight.2012. Accessed March 13 2023.https:\/\/www.optum.com\/content\/dam\/optum\/resources\/whitePapers\/Benefits\u2010of\u2010using\u2010both\u2010claims\u2010and\u2010EMR\u2010data\u2010in\u2010HC\u2010analysis\u2010WhitePaper\u2010ACS.pdf"},{"key":"e_1_2_6_15_1","volume-title":"CMS National Quality Strategy 2024","year":"2024"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.23089"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.5888\/pcd13.160221"},{"key":"e_1_2_6_18_1","volume-title":"RUCA data"},{"key":"e_1_2_6_19_1","volume-title":"Quality: traditional MIPS requirements 2024"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0382-9"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/PTS.0000000000001079"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-12-365"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6811a2"},{"key":"e_1_2_6_24_1","volume-title":"Global tuberculosis report 2022","year":"2022"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-013-2820-9"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120749"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25181"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140095"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2019.1612872"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/emi.2016.10"}],"container-title":["Arthritis Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/acr.25318","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T14:37:32Z","timestamp":1759415852000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/acr.25318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,18]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["10.1002\/acr.25318"],"URL":"https:\/\/doi.org\/10.1002\/acr.25318","archive":["Portico"],"relation":{},"ISSN":["2151-464X","2151-4658"],"issn-type":[{"value":"2151-464X","type":"print"},{"value":"2151-4658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,18]]},"assertion":[{"value":"2023-09-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}